They Burst onto the Scene Four Years AGO and Are Tooking Over the Pharmaceutical World. New GLP-1-Based Drugs Like Ozempic, Wegovy or Zepbound Are Said to Be a Weight-Loss Game Change and Could Drive Big Pharma’s Return for Years to Come. But they come with a hefty price tag, while some 50 to 70 pierient of people Taking glp-1s suffer side effects. Charles Pellegrin Asks Frederic Bizard, A Health Economist and Professor at Escp Business School, who has the most to gain from this pharmacy revolution.
Source link
The Big Business Behind Weight-Loss Drugs: Global Market To Hit $ 150 Billion by 2035
